Spyre Therapeutics, Inc.
SYRE$1.10B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWALTHAM95 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
4
Next Catalyst
This month
Market Overview
Stock performance and key metrics
SYRE News
Catalyst Timeline
4 upcoming, 0 past
Phase 2Next
SPY001 Phase 2 Est. Readout
June 2026~EstimatedSPY001645
Primary completion for SPY001 trial (NCT07012395) in Ulcerative Colitis
Source3 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SPY002-072 | Phase 2 | Rheumatoid Arthritis | - | - |
SPY001 | Phase 2 | Ulcerative Colitis | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply